Angels in MedCity holds fourth series of investor workshop and pitching event – Nov 2015
Angels in MedCity held its most recent investor workshop on the 12th of November.
The workshop was kindly hosted at Johnson & Johnson Innovation in central London and over 50 attendees participated in a session which explored the basics of angel investing and introduced the life sciences and healthcare sector to existing business angels.
Just two weeks later, Angels in MedCity’s fourth company presentation event was held at Lloyds Bank’s City of London HQ on Thursday 26th November, enabling six medical start-ups to pitch to an audience of 110 investors.
The presenting companies were chosen by a panel of experts for their high-growth potential and scientific quality and had received pitch training prior to the event. Focuses ranged from a novel technology for sustainable and prion-free collagen production from jellyfish, a medical device for minimal-invasive creation of dialysis access sites to novel technology for the generation of 3D models from CT scans for pre-operative surgery planning. After a short break a Cambridge-based company presented their technology and business model to reduce hospital-acquired infections with their anti-bacterial catheters followed by novel point-of-care devices to help GPs and cancer patients in determining blood-cell counts. Last up was a company with an innovative method for nucleic acid detection revolutionising tests for viruses and cancers alike. The companies were seeking to raise between £150k – £1.5m. The pitching sessions were followed by a drinks reception with the opportunity to network allowowing investors to ask their follow-up questions and find out more about the businesses.
The Angels in MedCity programme, launched in October 2014, provides impartial advice and information about investing in life sciences with the aim of building up a significant community of angels focused specifically on the healthcare and life sciences sector. Angel investment is a key source of funding for early stage companies but currently only a small proportion is invested in healthcare and life sciences companies, partly due to a low level of understanding of the sector amongst generalist investors.